Search 

JBI is a Midwest-based biotechnology company driven to develop a new class of therapies to treat patients with Alzheimer’s disease and other neurodegenerative diseases. 

JBI’s unique approach is able to lower the production of Amyloid Beta (Aβ), phosphorylated Tau (pTau) and toxic intracellular Aβ aggregates.  Our passion is to develop a therapy to restore the patient’s lifespan and improve patient quality of life.

JBI is focused on further developing its lead compound, JBI-009, based on the strength of compelling preclinical safety and efficacy results to date.

JBI’s approach represents a new wave in thinking about the treatment of AD.  Currently available drugs treat disease symptoms, rather than its suspected cause, and do so with limited success.  Most drugs in late-stage clinical development are attempting to address a likely cause of the disease, the accumulation of Aβ, by potently inhibiting the enzyme responsible for Aβ production.  As this enzyme has other important biological functions, this approach has seen early failures because of unacceptable side effects.  JBI's approach is unique in that it modulates the production of this enzyme rather than inhibits its activity.  JBI’s approach is expected to restore enzyme activity and Aβ production to normal levels with a favorable safety advantage.

JBI’s technology is also unique in that it targets cellular machinery within the Endoplasmic Reticulum (ER).  Most drug developers have focused on modifying activity that occurs either on the cell membrane or within the cell nucleus or cytosol.  JBI is one of the first, if not the first, to successfully target activity within the ER.  The discoveries employed by JBI have produced a lead compound that affects the enzyme responsible for controlling the rate-limiting step in Aβ production, penetrates the blood brain barrier, and shows no toxicity in IND feasibility safety studies.  In addition, work has begun on next generation compounds.  This ER-focused approach provides platform potential for future therapies to treat additional significant unmet medical needs.

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick NJ with an Innovation Center in Cambridge MA. The firm invests in a variety of fields within the life science sector including medical devices. J&J?s medical device investments are highly varied in both size and structure, the structure may involve milestone payments or may be an equity investment. J&J is interested in early stage medical device companies located globally.

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick, NJ, with an Innovation Center in Cambridge, MA. The firm invests in a variety of fields within the life science sector, including medical devices. J&J’s medical device investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment. J&J is interested in early stage medical device companies located globally.

Joslin Diabetes Center is a foundation based in Boston, Massachusetts that was founded in 1898, and is the world's largest diabetes and clinical care organization.

JT Pharma, the Pharmaceutical Division of Japan Tobacco (Akros Pharma, US; Torii, Japan) has broad therapeutic interests with a focus on cutting edge, innovative science and orally active small molecule therapeutics in diabetes, lipid regulation, osteoporosis (small molecule anabolic agents), HIV, HBV, fibrosis, pain, autoimmune diseases, inflammation (RA and OA), urological diseases, allergy, and new drug discovery and development tools. Torii, the marketing division of JT Pharma Division, is interested in late stage, i.e. late Ph3, close to registration drugs for the Japanese market. Torii’s areas of interest are: renal diseases including CKD and complications from hemodialysis, dermatology, atopic dermatitis (preferably given orally), psoriasis, allergy, i.e. antigen-specific immunotherapy, asthma, and rhinitis. JT Pharma and Torii are looking for commercializable technologies or products for collaborative R&D deals or in- licensing deals. 
JT Pharma seeks partnering opportunities, i.e., research and/or development collaborations, contract research and licensing arrangements, to enhance its own internal R&D efforts. Also, Japan Tobacco’s marketing division, Torii Pharmaceuticals, seeks late-stage clinical opportunities for the Japanese Market.
JT Pharma has an interest in early-stage, novel small molecule therapeutics focusing on diabetes,lipid regulation, HIV, HBV, autoimmune disease, inflammation (RA, OA, asthma, allergy), fibrosis, osteoporosis, overactive bladder, and pain (non-CNS) as well as new drug discovery and development tools. Compounds must have composition of matter patents.

Torii Pharmaceuticals is seeking drugs in clinical trials for licensing and marketing in Japan with a focus on dermatology (eczema, atopic dermatitis, psoriasis, onychomycosis, ), allergy, and kidney diseases.

JT Pharma is dedicated to the discovery, development, and sales of novel human therapeutics. In addition to the North American facilities mentioned above, most of JT Pharma’s new drug discovery and development work is performed within its Central Pharmaceutical Research Institute, located in Osaka. They also have a molecular biology research laboratory in Yokohama and a toxicology research facility in Hadano, Japan.

Jump Capital was founded in 2012 and is based in Chicago, with an additional office in San Francisco. The firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, Jump Capital typically allocates $2-15 million, and prefers to invest in Series B-C rounds. Jump Capital invests in the USA and Canada, and has previously invested in 6 healthcare companies.

Jump Capital invests in medical devices, diagnostics, digital and mobile health, and healthcare services. The firm is open to opportunities in any clinical indication. Jump Capital is only interested in devices and diagnostics that have in-human data.

JVC Investment Partners is a private investment firm that was founded in 2000 and is based in Chicago, Illinois. The firm focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.